Letrozole vs Clomiphene for PCOS — Which Ovulation Induction Works Better?
- Letrozole produces a 27.5% live birth rate vs 19.1% for clomiphene in the landmark Legro NEJM trial — a 44% relative improvement in live births.
- A 2026 meta-analysis of 32 RCTs confirmed letrozole's superiority across ovulation rate, pregnancy rate, live birth rate, and multiple pregnancy risk reduction.
- Clomiphene's anti-oestrogenic effect on the endometrium is the primary reason it underperforms — it produces a thinner, less receptive endometrial lining that reduces implantation even when ovulation occurs.
- A 2026 phenotype-specific study found letrozole produced 93.2% ovulation rates vs 77.9% for clomiphene — and the advantage was greatest in hyperandrogenic PCOS phenotypes.
- Multiple pregnancy risk is 58% lower with letrozole (RR 0.42) — an important safety advantage for single embryo development.
- Both medications are taken orally for 5 days early in the cycle. Neither requires injections. Letrozole is generally well tolerated with manageable side effects.
If you've been told you need ovulation induction for PCOS, you've almost certainly encountered two names: letrozole and clomiphene (also known as clomid or clomifene). For decades, clomiphene was the default first-line treatment — the medication most GPs and even some gynaecologists automatically prescribe. The evidence has now firmly shifted, and the question is no longer "which is better?" but "why are some practitioners still defaulting to clomiphene?"
This article explains the full comparison — mechanism, outcomes data, side effects, phenotype-specific considerations, and what to actually expect from treatment — so you can have an informed conversation with your prescriber about which medication is appropriate for your situation.
How they work — the mechanism matters
- Blocks aromatase enzyme, temporarily reducing oestrogen production
- Pituitary responds by releasing more FSH to compensate for low oestrogen
- Elevated FSH drives follicle development and ovulation
- Oestrogen returns to normal once treatment stops — no lasting anti-oestrogenic effect
- Endometrium develops normally under natural oestrogen after ovulation
- Half-life of ~45 hours — clears the body quickly before implantation window
- Blocks oestrogen receptors in the hypothalamus and pituitary
- Brain perceives low oestrogen and releases more FSH
- FSH drives follicle development and ovulation
- ⚠️ Also blocks oestrogen receptors in the endometrium and cervical mucus
- Endometrium becomes thinner and less receptive to implantation
- Half-life of ~5–7 days — remains in the body during the implantation window
This mechanistic difference explains why letrozole outperforms clomiphene on live birth rates despite sometimes similar ovulation rates. Both medications can induce ovulation successfully — but clomiphene's anti-oestrogenic effect on the endometrium reduces the chance that an ovulated egg, once fertilised, can successfully implant. Letrozole avoids this problem entirely because it works through a different mechanism that does not block oestrogen receptors in uterine tissue.
The evidence — head to head comparison
A systematic review and meta-analysis published January–February 2026, including 32 randomised controlled trials, found that letrozole offers higher rates of ovulation, pregnancy, and live birth, combined with a significantly lower risk of multiple pregnancy, making it a strong choice for first-line treatment in women with PCOS. This is the largest and most recent synthesis of the evidence and represents the current state of the literature definitively.
| Outcome | Letrozole | Clomiphene | Winner |
|---|---|---|---|
| Live birth rate (Legro NEJM trial) | 27.5% | 19.1% | Letrozole (+44% relative) |
| Live birth rate (Services Hospital 5-cycle RCT) | 25.4% | 10.9% | Letrozole (+133% relative) |
| Ovulation rate (2026 phenotype cohort) | 93.2% | 77.9% | Letrozole (p=0.002) |
| Cumulative ovulation rate (Legro) | 61.7% | 48.3% | Letrozole (p<0.001) |
| Multiple pregnancy risk | Significantly lower (RR 0.42) | Up to 40% of pregnancies were twins in some trials | Letrozole (58% risk reduction) |
| Endometrial thickness | Better — natural oestrogen effect | Thinner — anti-oestrogenic effect | Letrozole |
| Monofollicular development | 77.2% | 52.7% | Letrozole (safer, fewer multiples) |
| Congenital anomalies | No significant difference | No significant difference | Equal — both safe |
| Pregnancy loss rate | No significant difference | No significant difference | Equal |
A meta-analysis of 29 randomised controlled trials (3,952 participants, 7,633 ovulation induction cycles) found that for individuals with PCOS, treatment with letrozole compared with clomiphene resulted in a higher rate of ovulation induction, more pregnancies, and more live births. The relative risk for live birth was 1.49 (95% CI, 1.27–1.74) — meaning approximately 49% more live births with letrozole than with clomiphene across the evidence base.
Why the multiple pregnancy advantage matters
The 58% reduction in multiple pregnancy risk with letrozole is not just a statistical footnote — it is a clinically significant safety advantage. Multiple pregnancies (twins, triplets) carry substantially higher risks for both mother and babies: preterm birth, low birth weight, gestational hypertension, pre-eclampsia, and NICU admission are all significantly more common in multiple pregnancies.
In one trial, none of the patients in the letrozole group experienced a multiple pregnancy, whereas 40% of pregnancies in the clomiphene group were twins. This reflects clomiphene's tendency to stimulate multiple follicles — its less specific mechanism produces multifollicular development more frequently than letrozole's more targeted action. The desire to reduce multiple pregnancy risk is one of the primary reasons that reproductive endocrinologists strongly prefer letrozole for PCOS.
Phenotype-specific findings — letrozole's advantage is not uniform
A 2026 prospective cohort study evaluating letrozole and clomiphene across different PCOS phenotypes found that letrozole achieved significantly higher ovulation rates than clomiphene overall (93.2% vs. 77.9%, p=0.002) — and that the advantage was greatest in hyperandrogenic PCOS phenotypes. Women with PCOS phenotypes characterised by clinical or biochemical hyperandrogenism showed the most pronounced benefit from letrozole over clomiphene. For women with milder PCOS phenotypes (ovulatory dysfunction with polycystic morphology but without significant hyperandrogenism), the gap between the two medications was smaller.
This finding has practical implications: if your PCOS presentation includes significant androgen excess (acne, hirsutism, elevated testosterone) alongside anovulation, the evidence for choosing letrozole over clomiphene is particularly strong. For very mild PCOS presentations, clomiphene remains a reasonable alternative if letrozole is not available or not preferred for other reasons — but letrozole is still the better-evidenced choice.
Dosing — what to expect from each treatment
| Variable | Letrozole | Clomiphene |
|---|---|---|
| Starting dose | 2.5 mg/day | 50 mg/day |
| When taken | Days 2–6 of cycle (sometimes 3–7) | Days 2–6 or 3–7 of cycle |
| Duration per cycle | 5 days | 5 days |
| Dose escalation if no ovulation | 5 mg/day, then 7.5 mg/day | 100 mg/day, then 150 mg/day |
| Monitoring | Ultrasound to confirm follicle development and ovulation | Ultrasound to confirm follicle development and ovulation |
| How many cycles | Usually 3–6 cycles before reassessing | Usually 3–6 cycles before reassessing |
| Common side effects | Fatigue, dizziness, headache — generally mild and well tolerated | Hot flushes, mood changes, visual disturbances, bloating — more frequent and sometimes more disruptive |
| Effect on endometrium | Normal or improved thickness | Thinned — anti-oestrogenic effect reduces implantation window quality |
What about combining letrozole and Metformin?
Adding Metformin to letrozole is a well-studied approach — particularly for patients with significant insulin resistance where the metabolic environment impairs response to ovulation induction.
The evidence: Metformin combined with clomiphene outperforms clomiphene alone in insulin-resistant PCOS — this was established in multiple trials including the landmark Palomba trial. For letrozole, the combination with Metformin also shows benefit in patients with high HOMA-IR or who have previously failed letrozole alone. Most reproductive endocrinologists add Metformin alongside letrozole in PCOS patients with confirmed significant insulin resistance rather than as a universal combination.
Inositol combined with letrozole or clomiphene is an emerging area with promising data. Multiple RCTs show improvements in ovulation rate and endocrine parameters when myo-inositol is added to ovulation induction protocols in PCOS. Inositol improves insulin signalling and restores the ovarian MYO:DCI ratio — complementary mechanisms to letrozole's FSH-stimulating action. Discuss with your reproductive endocrinologist whether adding inositol to your letrozole protocol is appropriate for your situation.
When clomiphene is still used and why
Despite letrozole's clear evidence advantage, clomiphene is still prescribed in several contexts:
- Access and cost — clomiphene is older, off-patent, and cheaper in some healthcare systems where letrozole has not been licensed for fertility use (letrozole is licensed for breast cancer, not fertility, in several countries — though off-label use for fertility is now standard of care and well-established)
- GP prescribing habits — many GPs who are not fertility specialists were trained when clomiphene was the default and have not updated their practice
- Mild PCOS presentations — where the phenotype is mild and clinical preference leans toward the most familiar option
- Specific clinical scenarios — some practitioners prefer clomiphene for patients with very low oestrogen states where its receptor-blocking mechanism is specifically targeted
Clomiphene is not an ineffective medication — it does induce ovulation in most PCOS patients. But the evidence is now clear that letrozole produces significantly more live births per cycle while reducing multiple pregnancy risk. If you have been prescribed clomiphene and have not yet started treatment, it is entirely reasonable to ask your prescriber: "The 2023 International PCOS Guidelines and a 2026 meta-analysis of 32 trials recommend letrozole as first-line for PCOS — is letrozole appropriate for me?" This is an evidence-based question, not a challenge to your prescriber's judgement.
What happens after failed cycles — next steps
If 3–6 cycles of letrozole have not resulted in pregnancy, the next steps in the standard pathway are:
- Injectable gonadotropins — FSH injections stimulate follicle development more powerfully, requiring close ultrasound monitoring. Higher success rates than oral agents but with greater OHSS and multiple pregnancy risk.
- Laparoscopic ovarian drilling (LOD) — a surgical procedure that can restore ovulation in some clomiphene-resistant and letrozole-resistant PCOS patients, though its role is now limited by the availability of gonadotropins and IVF.
- IVF — typically offered after failed ovulation induction attempts, when additional infertility factors are present, or as a direct choice for patients who prefer to move to assisted reproduction.
Frequently asked questions
Is letrozole safe for fertility use?
Yes. Despite being licensed for breast cancer treatment rather than fertility (in most countries), letrozole has an excellent safety record in fertility use across multiple large trials. Congenital anomaly rates are no higher with letrozole than clomiphene or natural conception. The off-label status reflects its licensing history rather than any safety concern — reproductive endocrinologists worldwide consider it first-line standard of care for PCOS ovulation induction.
How do I know if letrozole is working?
Your clinic will typically schedule an ultrasound around day 10–14 of your cycle to confirm follicle development (target: one dominant follicle ≥18 mm). A second scan or blood test confirms ovulation has occurred. Some clinics use urine LH test strips to identify the LH surge that triggers ovulation — this typically occurs 24–36 hours before ovulation. Timing intercourse or IUI around confirmed ovulation maximises the chance of conception per cycle.
Can I take letrozole and inositol together?
Yes — there is no known interaction between letrozole and inositol, and there is emerging evidence that the combination improves outcomes compared to letrozole alone. Inositol should ideally be started at least 3 months before your first letrozole cycle to allow time to restore ovarian MYO:DCI balance and improve insulin sensitivity. Inform your reproductive endocrinologist of any supplements you are taking.
What if letrozole doesn't cause ovulation?
If the starting dose (2.5 mg) does not produce a dominant follicle confirmed on ultrasound, the dose is typically increased to 5 mg, then 7.5 mg in subsequent cycles. If three dose levels have been tried without successful ovulation, this is typically considered letrozole-resistant PCOS — which affects approximately 20–25% of patients — and injectable gonadotropins or IVF are the usual next steps.
Is IUI needed alongside letrozole?
Not necessarily — timed intercourse around confirmed ovulation is the standard approach for couples without male factor infertility. IUI (intrauterine insemination) combined with letrozole adds modest additional benefit in some protocols, particularly when mild male factor is present or when natural conception has not occurred despite confirmed ovulation over multiple cycles. Most reproductive endocrinologists will discuss the IUI option with you rather than making it automatic.
The fertility calorie calculator provides calorie targets, IR-adjusted carb limits, and eight key fertility nutrients for IVF and IUI preparation — including inositol, CoQ10, vitamin D, and folate.